Changes in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First‐Line Chemotherapy in Patients With Lymphoma

作者：Charlotte N Grønset, Mary Jarden, Jan Christensen, Casper Simonsen, Anders Tolver, Charlotte Suetta, Martin Hutchings · 发表于：Hematological Oncology · 年份：2025 · DOI：10.1002/hon.70154 · 被引用次数：2 · 研究领域：Nutrition and Health in Aging、Lymphatic System and Diseases、Cancer survivorship and care

Lymphomas are common cancers affecting the lymphatic system. Chemotherapy is a standard treatment, yet its impact on patient's physical capacity remains understudied. This study aimed to evaluate changes in body composition, muscle strength, and physical performance in patients diagnosed with lymphoma undergoing chemotherapy and to explore the potential association between muscle function and treatment tolerability. This single-center prospective cohort study included participants aged ≥ 18 years scheduled for first-line anthracycline-based chemotherapy for aggressive lymphoma. Patients were recruited and tested before treatment and after 6 months. Body composition (DXA), hand-grip strength, 30 s Sit-To-Stand test, 10-m gait speed and Quality of Life (EORTC-QLQ-C30) were assessed. Low muscle strength, lean mass and gait speed were defined according to the European Working Group on Sarcopenia in Older People (EWGSOP2). Fifty-eight patients (42 males) with a median age of 62 years (range 18-87) completed both test points and were included in the analysis. From baseline to follow-up, total lean mass decreased by 1.70 kg (95% CI -2.55 to -0.85, p = 0.0002), body fat percentage increased by 2.3% (95% CI 1.19 to 3.41, p = 0.0001), handgrip strength decreased by 1.93 kg (95% CI -3.15 to -0.71, p = 0.002), whereas Sit-To-Stand performance increased by 1.4 repetitions (95% CI 0.15 to 2.69, p = 0.03). No changes were observed in appendicular lean mass, body weight, or gait speed. Furth...